Drug Trial Radar · NCT07776509
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Aug 24, 2026
Primary completion
Aug 9, 2028
Study completion Aug 9, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment.
Conditions
- Obesity or Overweight
- Weight-Related Comorbidity
- With/Without Diabetes Mellitus, Type 2
Interventions
LenbelintideDrug
IMP injected subcutaneously, once a week.
PlaceboDrug
Placebo matching IMP dose injected subcutaneously, once a week.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in body weight from baseline at 68 weeks of treatmentTime frame: 68 weeks
Locations
96 sites in 11 countries. Site status is shown where the registry gives one.
Research Site
Escondido, California · Not yet recruiting
Research Site
Lincoln, California · Recruiting
Research Site
Walnut Creek, California · Not yet recruiting
Research Site
Jacksonville, Florida · Not yet recruiting
Research Site
Jacksonville, Florida · Not yet recruiting
Research Site
Stockbridge, Georgia · Recruiting
Research Site
Woodstock, Georgia · Recruiting
Research Site
Champaign, Illinois · Recruiting
Research Site
Chicago, Illinois · Recruiting
Research Site
Beltsville, Maryland · Not yet recruiting
Research Site
Oxon Hill, Maryland · Not yet recruiting
Research Site
Kansas City, Missouri · Recruiting
Research Site
Las Vegas, Nevada · Not yet recruiting
Research Site
Somerset, New Jersey · Not yet recruiting
Research Site
Statesville, North Carolina · Recruiting
Research Site
Fargo, North Dakota · Recruiting
Research Site
Columbus, Ohio · Recruiting
Research Site
Portland, Oregon · Not yet recruiting
Research Site
Smithfield, Pennsylvania · Recruiting
Research Site
Franklin, Tennessee · Not yet recruiting
Research Site
Houston, Texas · Recruiting
Research Site
Manassas, Virginia · Not yet recruiting
Research Site
Renton, Washington · Withdrawn
Research Site
Buenos Aires, Argentina · Recruiting
Research Site
CABA, Argentina · Recruiting
Research Site
Ciudad de Buenos Aires, Argentina · Recruiting
Research Site
Ramos Mejía, Argentina · Not yet recruiting
Research Site
Rosario, Argentina · Recruiting
Research Site
San Nicolás, Argentina · Not yet recruiting
Research Site
Belo Horizonte, Brazil · Not yet recruiting
Research Site
Campinas, Brazil · Recruiting
Research Site
Campinas, Brazil · Not yet recruiting
Research Site
São Paulo, Brazil · Not yet recruiting
Research Site
São Paulo, Brazil · Not yet recruiting
Research Site
São Paulo, Brazil · Not yet recruiting
Research Site
Calgary, Alberta, Canada · Recruiting
Research Site
Calgary, Alberta, Canada · Recruiting
Research Site
Surrey, British Columbia, Canada · Recruiting
Research Site
Vancouver, British Columbia, Canada · Recruiting
Research Site
Guelph, Ontario, Canada · Recruiting
Showing 40 of 96 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.